Banco Santander SA (SAN)

6.78
0.01 0.07
NYSE : Finance
Prev Close 6.78
Open 6.79
Day Low/High 6.77 / 6.79
52 Wk Low/High 6.04 / 7.57
Volume 58.40K
Avg Volume 7.56M
Exchange NYSE
Shares Outstanding 16.14B
Market Cap 109.83B
EPS 0.50
Div & Yield 0.20 (2.92%)

Latest News

Santander Holdings USA Declares Quarterly Dividend On Preferred Stock

Sanofi: EMA To Review Sotagliflozin As Potential Treatment For Type 1 Diabetes
Previously Announced Tender Offers By Sanofi To Acquire Ablynx Will Commence On April 4, 2018

Previously Announced Tender Offers By Sanofi To Acquire Ablynx Will Commence On April 4, 2018

Sanofi: Availability Of The Pre-quarterly Results Communication

Sanofi: Availability Of The Pre-quarterly Results Communication

Jim Cramer: When There's Nothing to Buy, People Sell

Jim Cramer: When There's Nothing to Buy, People Sell

No sector offered respite from Thursday's tariff-inspired selloff.

Santander Bank And Greater Providence Chamber Of Commerce Host 18th Annual Economic Outlook Event For Rhode Island Business Leaders

Santander Bank And Greater Providence Chamber Of Commerce Host 18th Annual Economic Outlook Event For Rhode Island Business Leaders

Real-Time Survey Reveals that 65% of Business Leaders Believe Rhode Island's Economy Will Be in Better Shape in Next 12 Months

Santander Bank Raises Its Prime Rate To 4.75%

Santander Bank Raises Its Prime Rate To 4.75%

Sanofi Successfully Prices EUR 8 Billion Of Bond Issues

Sanofi Successfully Prices EUR 8 Billion Of Bond Issues

Sanofi And Regeneron Announce Plans To Make Praluent® More Accessible And Affordable For Patients With The Greatest Health Risk And Unmet Need

Sanofi And Regeneron Announce Plans To Make Praluent® More Accessible And Affordable For Patients With The Greatest Health Risk And Unmet Need

Sanofi: Praluent® (alirocumab) Significantly Reduced Risk Of Cardiovascular Events In High-risk Patients, And Was Associated With Lower Death Rate

Sanofi: Praluent® (alirocumab) Significantly Reduced Risk Of Cardiovascular Events In High-risk Patients, And Was Associated With Lower Death Rate

Sanofi Completes Acquisition Of Bioverativ Inc.

Sanofi Completes Acquisition Of Bioverativ Inc.

Evotec And Sanofi In Exclusive Talks To Create An Evotec-led Infectious Disease Open Innovation R&D Platform

Evotec And Sanofi In Exclusive Talks To Create An Evotec-led Infectious Disease Open Innovation R&D Platform

Sanofi: Filing Of The 2017 U.S. Form 20-F And French « Document De Reference » Containing The Annual Financial Report

Sanofi: Filing Of The 2017 U.S. Form 20-F And French « Document De Reference » Containing The Annual Financial Report

Sanofi's Board Of Directors Proposes Appointment Of Emmanuel Babeau As New Independent Director

Sanofi's Board Of Directors Proposes Appointment Of Emmanuel Babeau As New Independent Director

Sanofi : FDA To Review Dupixent® (dupilumab) As Potential Treatment For Moderate-to-severe Asthma

Sanofi : FDA To Review Dupixent® (dupilumab) As Potential Treatment For Moderate-to-severe Asthma

Sanofi Announces Receipt Of Antitrust Clearances In Connection With The Acquisition Of Ablynx

Sanofi Announces Receipt Of Antitrust Clearances In Connection With The Acquisition Of Ablynx

Sanofi: Hart-Scott-Rodino Waiting Period Expires For Sanofi's Acquisition Of Bioverativ

Sanofi: Hart-Scott-Rodino Waiting Period Expires For Sanofi's Acquisition Of Bioverativ

Results From Innovative Phase 2 Tuberculosis Vaccine Trial Offer Potential For New BCG Revaccination Strategies, Hope For Subunit Vaccines

Results From Innovative Phase 2 Tuberculosis Vaccine Trial Offer Potential For New BCG Revaccination Strategies, Hope For Subunit Vaccines

Study is the First "Prevention of Infection" Trial Conducted for Tuberculosis, the World's Leading Infectious Disease Killer

First Targeted Treatment For Adults With Moderate-to-severe Atopic Dermatitis, Dupixent™, Now Available In Canada

First Targeted Treatment For Adults With Moderate-to-severe Atopic Dermatitis, Dupixent™, Now Available In Canada

Sanofi Commences Tender Offer For Acquisition Of Bioverativ Inc.

Sanofi Commences Tender Offer For Acquisition Of Bioverativ Inc.

Sanofi Delivers 2017 Business EPS(1) In Line With Guidance

Sanofi Delivers 2017 Business EPS(1) In Line With Guidance

Sanofi: Sanofi, DNDi Seek European Medicines Agency Review For Sleeping Sickness Treatment

Sanofi: Sanofi, DNDi Seek European Medicines Agency Review For Sleeping Sickness Treatment

Sanofi To Acquire Ablynx For €3.9 Billion

Sanofi To Acquire Ablynx For €3.9 Billion

Santander Bank Gives Front-line Colleagues A Raise; Increases Minimum Hourly Wage

Santander Bank Gives Front-line Colleagues A Raise; Increases Minimum Hourly Wage

Dominion Energy, U.S. Concrete, AMD: 'Mad Money' Lightning Round

Dominion Energy, U.S. Concrete, AMD: 'Mad Money' Lightning Round

Jim Cramer's bullish on Dominion Energy, U.S. Concrete, Banco Santander, Republic First Bancorp, First Horizon National, and NVIDIA.

The Ups and Downs of This Market: Cramer's 'Mad Money' Recap (Wednesday 1/24/18)

The Ups and Downs of This Market: Cramer's 'Mad Money' Recap (Wednesday 1/24/18)

Jim Cramer maps the roller coaster ride of Wednesday's session: Use strength to ring the register, use weakness to buy your favorites.

Sanofi: Availability Of The Pre-quarterly Results Communication

Sanofi: Availability Of The Pre-quarterly Results Communication

Sanofi To Acquire Bioverativ For $11.6 Billion

Sanofi To Acquire Bioverativ For $11.6 Billion

Sanofi To Acquire Bioverativ For $11.6 Billion

Sanofi To Acquire Bioverativ For $11.6 Billion

Sanofi Appoints Dominique Carouge Executive Vice President Head Of Business Transformation And Member Of The Executive Committee

Sanofi Appoints Dominique Carouge Executive Vice President Head Of Business Transformation And Member Of The Executive Committee

Load More

From Our Partners

Sanofi Finance Chief to Leave After Almost a Decade at Drugmaker
Bloomberg

Sanofi to Sell Generics for $2.4 Billion to Focus on Biotech
Bloomberg

Santander launches a blockchain-based foreign exchange service that uses Ripple’s technology
CNBC

Surface Oncology Proposes IPO Terms
SeekingAlpha

Surface Oncology Files For $75 Million IPO
SeekingAlpha

Banco De Sabadell: Higher Profitability May Lead To A Re-Rating Of Its Shares
SeekingAlpha

Banco Santander upgraded to Outperform from Market Perform at Keefe Bruyette
The Fly

Deutsche Bank, Banks And The USD: The Writing (Off) Is On The Wall (Street)
SeekingAlpha

Senate passes bill easing Dodd-Frank
SeekingAlpha

Regeneron, Sanofi Cut Heart Drug's Price to Spur Greater Use
Bloomberg

Caixabank: Investment Case Is Based On Income
SeekingAlpha

Wall Street Breakfast: Europe Goes After American Brands
SeekingAlpha

Senate to vote on Dodd-Frank rollback
SeekingAlpha

Banco Santander upgraded to Outperform from Market Perform at BBVA
The Fly

Why Is Ray Dalio Shorting Banco Santander?
SeekingAlpha

Watchlist

Trending
Why the Stock Market Won't Crash When 10-Year Yields Smash Through 3%
Should You Invest In DowDuPont Now?
3 Things Investors Must Know for Monday
Waste Management: Cramer's Top Takeaways
Halliburton Falls Despite Revenue Jump